nab-paclitaxel + sitravatinib + tislelizumab

nab-paclitaxel + sitravatinib + tislelizumab is an investigational combination therapy comprising three agents with distinct mechanisms of action, being explored primarily for the treatment of solid tumors, including gastrointestinal and other advanced cancers. nab-paclitaxel is an albumin-bound formulation of paclitaxel that acts as a microtubule inhibitor, disrupting cell division by stabilizing microtubules and preventing their depolymerization. This formulation enhances tumor delivery via albumin-mediated transport and may also deplete tumor stroma through interactions with secreted protein acidic and rich in cysteine (SPARC)[1][2][3][4][5]. Sitravatinib is a small molecule tyrosine kinase inhibitor targeting multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and immune modulation (not detailed in the provided results but known from established literature). Tislelizumab is a humanized monoclonal antibody that targets programmed death receptor 1 (PD-1), blocking its interaction with PD-L1/PD-L2 to restore T-cell function and promote immune-mediated antitumor activity[6][8][10]. The rationale for combining these agents lies in their complementary actions on cancer cells—direct cytotoxicity from nab-paclitaxel, inhibition of oncogenic signaling pathways by sitravatinib, and enhancement of antitumor immunity via checkpoint blockade by tislelizumab.